Bristol Myers Squibb outperformed the broader market in the latest session with a 1.22% gain, even as it faces financial ...

Sildenafil citrate during labor did not improve perinatal outcomes potentially related to intrapartum hypoxia despite ...

The latest trading day saw Bristol Myers Squibb (BMY) settling at $49, representing a +1.22% change from its previous close.

This was the stock's second consecutive day of gains.

Here are seven new shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists. Editor’s note: The drugs listed are in alphabe ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

A groundbreaking lung cancer screening project co-led by the University of Kentucky Markey Cancer Center and the University ...

Giving patients more direct control over their healthcare data is a frequent talking point among healthcare leaders. | The ...

Califano has received honoraria and consultancy fees from AstraZeneca, Boeringher Ingelheim, Lilly Oncology, Roche, Pfizer, MSD, Bristol Myers Squibb, Takeda, Biontech, Pharnamar, Janssen, Bayer, and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Neuroscience technology company Brooklyn Health is using artificial intelligence to target a fundamental problem in neurology ...